Research
Hormonal
Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
If you have obesity and existing heart disease, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly reduce your body weight and lower your risk of heart attacks, strokes, and death, offering strong protection for your heart.
StrongSupportsVERY_HIGH confidence
With a weekly dose of 2.4 mg semaglutide, a 12.4% (95% confidence interval −13.4 to −11.5) reduction in body weight could be achieved when compared with placebo. ... the primary endpoint (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was reduced by 20% (hazard ratio 0.80, 95% confidence interval 0.72-0.90).
Why this rating
Based on the SELECT trial, a large-scale randomized clinical trial.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
narrative_reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →